The DOI matches its Crossref record; 128 of the 129 references it cites were found in a registry or an index.
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and current guidelines recommend the use of GLP-1 receptor agonists in patients with diabetes who need cardiovascular risk reduction, weight management, or both. 38,39”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Weight management programmes have been shown to reduce the progression of type 2 diabetes, improve glycaemia, and reduce the need for glucose-lowering medications. 1”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Research works printed but not linked: 1
- Wing, 2013, Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes, N Engl J Med, 369, 145, 10.1056/NEJMoa1212914 · DOI · Paper page
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Self-citationMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
“%) may lead to diabetes remission (237).”
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00385-6 · Cited by 186
Boutari, C., DeMarsilis, A., & Mantzoros, C. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110773 · Cited by 161
New insights into the treatment of obesity
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15077 · Cited by 158
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Kirkpatrick, C. F., Sikand, G., Petersen, K. S., Anderson, C. A. M., Aspry, K. E., Bolick, J. P., Kris‐Etherton, P. M., & Maki, K. C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.099 · Cited by 145
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 109
Lyu, H., Zhao, S. S., Zhang, L., Wei, J., Li, X., Li, H., Liu, Y., Yin, P., Norvang, V., Yoshida, K., et al. (2023) · BMJ · doi:10.1136/bmj-2022-073435 · Cited by 75
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Revised definition of obesity in Asian Indians living in India
Misra, A., Vikram, N. K., Ghosh, A., Ranjan, P., & Gulati, S. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102989 · Cited by 75
Bays, H. E., Bindlish, S., & Clayton, T. L. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100056 · Cited by 74
“Strong and consistent evidence supports obesity management as delaying the progression from prediabetes to type 2 diabetes, improving glycemia in patients with T2DM, reducing the need for glucose-lowering medications, and promoting sustained diabetes remission through at least 2 years [133].”
BackgroundInfluentialZhong, P., Tan, S., Zhu, Z., Zhu, Z., Liang, Y., Huang, W., & Wang, W. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3707 · Cited by 67
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 63
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
Caruso, I., Gioia, L. D., Molfetta, S. D., Cignarelli, A., Palmer, S. C., Natale, P., Strippoli, G. F., Perrini, S., Natalicchio, A., Laviola, L., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102181 · Cited by 65
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“According to the American Diabetes Association Standards of Care 2024, metformin should be used as the initial first‑line therapy for T2D in patients not meeting the criterion for the pres‑ ence of ASCVD/increased risk for ASCVD, heart failure or chronic kidney disease [141].”
MethodKnowledge about type 2 diabetes: its impact for future management
Ferreira, P. L., Morais, C., Pimenta, R. E., Ribeiro, I., Amorim, I., Alves, S. M., & Santiago, L. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1328001 · Cited by 71
Credibility of ChatGPT in the assessment of obesity in type 2 diabetes according to the guidelines
Barlas, T., Altınova, A. E., Aktürk, M., & Törüner, F. B. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01410-5 · Cited by 56
Zhong, V. W., Yu, D., Zhao, L., Yang, Y., Li, X., Li, Y., Huang, Y., Ding, G., & Wang, H. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0442 · Cited by 54
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
“11 At least 150 min per week of moderate-intensity aerobic activity, spread over at least 3 days of the week, is recommended for most adults with T2D.”
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
Szczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Pacholak-Klimas, A., Ede, G., Sethi, S., Łojko, D., Bartoń, K., Berry, K., Deptuła, A., et al. (2025) · Nutrients · doi:10.3390/nu17060965 · Cited by 47
“Standard weight loss diets focus on calorie restriction, typically recommending that the daily energy allowance be 500 to 1000 kcal lower than the body’s requirements [62,63].”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Prior to the 2014 approval of 3-mg liraglutide for this indication (70), most AOMs barely achieved the ≥ 5% threshold for clinically meaningful weight loss (71–73).”
Wang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06142-3 · Cited by 42
Kick, A., M'Rabet‐Bensalah, K., Acquistapace, F., Amadid, H., Ambühl, R. A., Braae, U. C., Item, F., Schultes, B., Züger, T., & Rudofsky, G. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01525-y · Cited by 41
“The achievement and maintenance of glycaemic control is the key target for people living with type 2 diabetes (T2D), with weight loss also an important target for people with overweight and obesity [2, 3].”
Merovci, A., Finley, B., HANSIS-DIARTE, A. A., Neppala, S., Abdul‐Ghani, M. A., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004199 · Cited by 40
“12 26 To examine WHAT IS ALREADY KNOWN ON THIS TOPIC ⇒ Ketogenic diets promote weight loss, improve glycemic control, and reduce insulin resistance.”
Chen, J., Li, Y., Niu, Z., He, Z., Xie, Y. J., Hernández, J., Huang, W., Wang, H., & Guangzhou Diabetic Eye Study Group (2024) · JMIR Public Health and Surveillance · doi:10.2196/48120 · Cited by 38
“This is in line with the most recent American Diabetes Association guideline that advocates lifestyle improvement and obesity management in patients with diabetes [17,73].”
ResultHuang, Z., Zhuang, X., Huang, R., Liu, M., Xu, X., Fan, Z., Dai, R., Li, H., Xiong, Z., Guo, Y., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0219 · Cited by 39
Yang, X., Sun, J., & Zhang, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1343002 · Cited by 46
Minari, T. P., Manzano, C. F., Tácito, L. H. B., Yugar, L. B. T., Sedenho‐Prado, L. G., Rubio, T. D. A., Pires, A. C., Vilela-Martin, J. F., Cosenso‐Martin, L. N., Moreno, H., et al. (2024) · Nutrients · doi:10.3390/nu16091378 · Cited by 34
Natural Compounds for Preventing Age-Related Diseases and Cancers
Ki, M., Youn, S., Kim, D. H., & Pack, S. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147530 · Cited by 32
Liu, Y., Chen, Y., Ma, J., Lin, J., Liu, C., Li, X., Xu, Y., Kuang, H., Shi, L., Xue, Y., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081820 · Cited by 38
Nitecki, M., Gerstein, H. C., Balmakov, Y., Tsur, E., Babushkin, V., Michaeli, T., Afek, A. B., Pinhas‐Hamiel, O., Cukierman‐Yaffe, T., & Twig, G. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02007-y · Cited by 32
“Further, BMI is the measure preferred by the American Diabetes Association (ADA) for weight surveillance among individuals with pre-diabetes or diabetes [9].”
BackgroundDiabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study
Meira, I., Menino, J., Ferreira, P., Leite, A. R., Gonçalves, J., Ferreira, H. U., Ribeiro, S., Moreno, T., Silva, D. F., Pedro, J. M. P., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07592-9 · Cited by 31
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Ma, Z., Jin, K., Yue, M., Chen, X., & Chen, J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/5891532 · Cited by 29
“In addition, the American Diabetes Association (ADA) also recommends weight loss based on intensive lifestyle interventions to achieve optimal control of traditional cardiovascular risk factors in overweight or obese adults with type 2 diabetes [16].”
BackgroundPerspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Comprehensive care for patients with obesity: An Obesity Medicine Association Position Statement
Fitch, A., Alexander, L., Brown, C. F., & Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100070 · Cited by 24
Effectiveness of a Nutrition Education Program for Patients with Type 2 Diabetes Mellitus
Gortzi, O., Dimopoulou, M., Androutsos, O., Vraka, A., Gousia, H., & Bargiota, Α. (2024) · Applied Sciences · doi:10.3390/app14052114 · Cited by 32
Mateos, I. C., Morales, C., López, M. L., & Vilches‐Arenas, Á. (2025) · Journal of Medical Internet Research · doi:10.2196/60758 · Cited by 27
Tsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15312 · Cited by 28
Lipids as the link between central obesity and diabetes: perspectives from mediation analysis
Lu, S., Kuang, M., Qiu, J., Li, W., Zhang, M., Sheng, G., Zou, Y., & Peng, X. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01764-5 · Cited by 23
Amerkamp, J., Benli, S., Isenmann, E., & Brinkmann, C. K. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.016 · Cited by 28
Warmbrunn, M. V., Attaye, I., Aron‐Wisnewsky, J., Rampanelli, E., van der Vossen, E. W. J., Hao, Y., Koopen, A. M., Bergh, P., Stols‐Gonçalves, D., Mohamed, N., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2370616 · Cited by 24
Li, Z., Han, Z., Sun, R., Xuan, X., & Huang, C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s539822 · Cited by 23
Zu, C., Liu, M., Su, X., Wei, Y., Meng, Q., Liu, C., Ye, Z., Gan, X., Zhang, Y., He, P., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1727 · Cited by 21
Treat Obesity to Treat Type 2 Diabetes Mellitus
Sulu, C., & Yumuk, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01536-3 · Cited by 24
“Considering these data, the American Diabetes Association (ADA) strongly recommends ILI that support weight loss in high-risk individuals [47].”
BackgroundMajanović, S. K., Belančić, A., Bukša, I., Morić, N., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5010005 · Cited by 23
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“It is well established that carrying excess weight, or being obese, is a major risk factor for the development of T2DM [8,9].”
Mao, X., Zhang, X., Henry, L. L., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf163 · Cited by 20
Breaking down silos: the multifaceted nature of obesity and the future of weight management
Heeren, F. A. N., Darcey, V. L., Deemer, S. E., Menon, S., Tobias, D. K., & Cardel, M. I. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0215 · Cited by 23
Ding, Y.-F., Deng, A., Qi, T., Yu, H., Wu, L., & Zhang, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01554-y · Cited by 18
“Among the numerous risk factors for T2DM, elevated BMI is a significant predisposing factor[4].”
Shinde, S., Thieu, V. T., Kwan, A. Y. M., Houghton, K., Meyers, J., & Schapiro, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01511-4 · Cited by 19
“…1-year and 5-year follow-up cohorts were reported to have undergone bariatric surgery, which is commonly recommended for the effective remission and prevention of T2D in adults with a higher BMI showing no sustained weight loss and improvement in comorbidities with nonsurgical methods [8, 32, 33].”
BackgroundVelji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 21
“Efective obesity management is a critical component in preventing T2DM and reducing the risk of cardiovascular disease or advanced chronic liver disease [2, 3].”
Solis‐Herrera, C., & Triplitt, C. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15327 · Cited by 18
Mena-Hernández, D. R., Jiménez-Domínguez, G., Méndez, J. D., Olvera‐Hernández, V., Martínez‐López, M. C., Guzmán‐Priego, C. G., Reyes-López, Z., Ramos-García, M., Juárez‐Rojop, I. E., Zavaleta-Toledo, S. S., et al. (2024) · Nutrients · doi:10.3390/nu16142187 · Cited by 17
“This result is important, since it is known that even a small weight reduction can lower the risk of heart disease, inflammation, hypertension, and type 2 diabetes [37].”
BackgroundHankosky, E. R., Desai, K. R., Chinthammit, C., Grabner, M., Stockbower, G. E., He, X., Mojdami, D., Wenziger, C. M., & Gibble, T. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101636 · Cited by 21
Eid, S., O’Brien, P. D., Kretzler, K. H., Jang, D., Mendelson, F. E., Hayes, J. M., Carter, A., Zhang, H., Pennathur, S., Brosius, F. C., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202300354r · Cited by 16
Alghamdi, A., Alsaeddi, A., Malki, H., & Alsaedi, A. A. (2023) · Cureus · doi:10.7759/cureus.44644 · Cited by 16
Nutritional Aspects to Cardiovascular Diseases and Type 2 Diabetes Mellitus
Billingsley, H., Heiston, E. M., Bellissimo, M. P., Lavie, C. J., & Carbone, S. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02018-x · Cited by 17
“Intentional weight loss achieved with lifestyle interventions is associated with significant improvements in glycemic control, micro-and macrovascular complications, as well as quality of life [16].”
BackgroundInfluentialReurean‐Pintilei, D., Potcovaru, C.-G., Salmen, T., Mititelu-Tarțău, L., Cinteză, D., Lazăr, S., Stoian, A. P., Timar, R. Z., & Timar, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082196 · Cited by 15
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 16
Self-citationLi, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19
Orioli, L., & Thissen, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554617 · Cited by 19
Effect of pharmacist interventions on the management of overweight and obesity: A systematic review
Alhomoud, I. S., Cook, E., Patel, D., Brown, R. E., & Dixon, D. L. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102058 · Cited by 14
Li, X., Donnelly, L. A., Slieker, R. C., Beulens, J. W. J., Hart, L. M. ‘., Elders, P. J. M., Pearson, E. R., van Giessen, A., Leal, J., & Feenstra, T. (2024) · Diabetologia · doi:10.1007/s00125-024-06147-y · Cited by 15
“HbA 1c [28, 29], 0.9 mmol/l HDL-cholesterol [30], 25 kg/m 2 BMI [31]) will either remain or progress to the RHAP-MD subgroup over time, whereas insufficient risk factor control could result in increased progression to severe subgroups.”
BackgroundInfluentialPeters, A. L., Buzzetti, R., Lee, C. J., Pavo, I. J., Liu, M., Karanikas, C. A., & Paik, J. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae372 · Cited by 18
Klonoff, D. C., Levy, B. L., Jaasma, M. J., Bharara, M., Edgar, D. R., Nasr, C. E., Caraway, D. L., Petersen, E., & Armstrong, D. G. (2024) · Journal of Pain Research · doi:10.2147/jpr.s463383 · Cited by 14
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.02.001 · Cited by 25
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
Chen, J., Li, Y., Niu, Z., He, Z., Xie, Y. J., Hernández, J., Huang, W., Wang, H., & The Guangzhou Diabetic Eye Study Group (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15598 · Cited by 13
“68 From a public health perspective, regular monitoring of BMI may assist in identifying a broader range of patients with T2D at risk for DMC. Early detection, followed by timely intervention, may help to improve patients' quality of life and reduce disease burden.”
BackgroundLi, X., van Giessen, A., Altunkaya, J., Slieker, R. C., Beulens, J. W. J., Hart, L. M. ‘., Pearson, E. R., Elders, P. J. M., Feenstra, T., & Leal, J. (2023) · Diabetes Care · doi:10.2337/dc22-2170 · Cited by 12
Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system
Xiao, Y., Zhou, M., & Xiao, W. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02415-w · Cited by 13
“Therefore, for diabetic patients with higher BMI, the integration of exercise, nutrition changes and GLP-1RAs treatment seems to be a promising approach for enhancing the healthy weight loss [59].”
Orozco‐Beltrán, D., Mata‐Cases, M., Artola‐Menéndez, S., Guisasola, F. Á., Cuenca, A. M. C., & Pérez, A. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.002 · Cited by 13
Ler, P., Ploner, A., Finkel, D., Reynolds, C. A., Zhan, Y., Jylhävä, J., Aslan, A. K. D., & Karlsson, I. (2023) · GeroScience · doi:10.1007/s11357-023-01032-9 · Cited by 12
SEA 2024 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.06.001 · Cited by 18
Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, and Treatment
Burns, C., & Francis, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_34 · Cited by 13
Frías, J. P., Galindo, R. J., Wang, H., Malik, R., Chivukula, K. K., & Maldonado, J. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad495 · Cited by 11
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Hunter, T. M., Cao, D., Murphy, M., Jouravskaya, I., Liao, B., & Bays, H. E. (2025) · Obesity · doi:10.1002/oby.70011 · Cited by 10
“Treatment with obesity pharmacotherapy, as an adjunct to lifestyle interventions, is recommended for sustained weight reduction and improving HRQoL [5].”
False Beliefs About Diabetes Mellitus in the Kurdistan Region of Iraq: A Population-Based Study
Rashad, B. H., Abdi, B. A., Naqid, I. A., Hussein, N. R., Mosa, A. A., Dawoud, L. H., Elyas, R. I., & Abdulrahman, H. A. (2023) · Galician Medical Journal · doi:10.21802/gmj.2023.3.1 · Cited by 10
Mody, R., Meyer, K. L., Ward, J. M., & O’Day, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01470-w · Cited by 10
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
“Current guidelines from the American Diabetes Association, therefore, recommend the use of GLP-1 analogues in obese diabetic patients who need to manage their body weight and reduce the risk of cardiovascular disease [137,138].”
BackgroundLamichhane, G., Lee, D., Franks, R., Olawale, F., Jin, J.-B., Egan, J. M., & Kim, Y. (2024) · Biology · doi:10.3390/biology13070472 · Cited by 13
“Therefore, controlling body weight is an effective strategy for preventing NAFLD [26] and type 2 diabetes [27].”
BackgroundSantos, B. D. C., Alves, L. F., Rocha, V. D. S., Ruiz, Á. H., Silva, A. M. D. O. E., & Pires, L. V. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae071 · Cited by 10
Minari, T. P., Manzano, C. F., Yugar, L. B. T., Sedenho‐Prado, L. G., Rubio, T. D. A., Tácito, L. H. B., Pires, A. C., Vilela-Martin, J. F., Cosenso‐Martin, L. N., Ludovico, N. D., et al. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.026 · Cited by 10
Chen, G., Sha, Y., Wang, K., Tang, R., Zhai, Z., Wang, Z., & Chen, Y. (2025) · Cureus · doi:10.7759/cureus.78492 · Cited by 9
“The frequency and effectiveness of assessments vary over time to ensure that potential problems can be effectively detected and managed at an early stage and stabilized over the long term [152].”
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
Kapantais, D., & Tsoutsanis, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248792 · Cited by 11
“…and injectable formulation, and, more recently, GLP-1R-GIPR co-agonists, such as tirzepatide (at 10 mg or 15 mg), are all recommended on the American Diabetes Association (ADA) Professional Practice Committee guidance for obesity and weight management for the prevention of type 2 diabetes [10].”
Fujihara, K., KHIN, L. M., Murai, K., Yamazaki, Y., Tsuruoka, K., Yagyuda, N., Yamazaki, K., Maegawa, H., Tanaka, S., Kodama, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15206 · Cited by 10
“Diabetes emphasized weight management and noted that a weight loss of 3-7% can improve glycaemia and ameliorate other intermediate cardiovascular risk factors.(11) In addition, larger and sustained weight loss (>10%) usually confers greater benefits including those related to cardiovascular disease in obese patients a…”
BackgroundResultInfluentialOzcariz, E., Guardiola, M., Amigó, N., Valdés, S., Oualla‐Bachiri, W., Rehues, P., Rojo‐Martínez, G., & Ribalta, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02488-5 · Cited by 8
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01794-9 · Cited by 11
Thomas, S., Besecker, B. Y., Choe, Y. S., & Christofides, E. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1399410 · Cited by 8
“One of the most important and recognized steps in diabetes management is the implementation of lifestyle recommendations that include improving diet and exercise along with behavioral strategies in conjunction with prescribed medications (2 – 6).”
BackgroundKarakaya, R. E., & Elibol, E. (2025) · BMC Public Health · doi:10.1186/s12889-024-21248-4 · Cited by 8
PNPLA3 gene variation modulates diet-induced improvement in liver lipid content in type 2 diabetes
Pafili, K., Zaharia, O., Straßburger, K., Knebel, B., Herder, C., Huttasch, M., Karusheva, Y., Kabisch, S., Strom, A., Nowotny, B., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.02.032 · Cited by 8
Medical imaging in the assessment of cardiovascular disease risk
Alcántara, J. M. A., Idoate, F., & Labayen, I. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000960 · Cited by 10
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Gabbay, R. A., & American Diabetes Association
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S128-S139
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810466
- OpenAlex
- W4311182596
- Cited by
- 244
- References
- 129
- Citations by year
- 2026: 22 · 2025: 58 · 2024: 95 · 2023: 68
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight management, type 2 diabetes, diabetes prevention, diabetes treatment, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrinology, Humans, Obesity, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.